Core Viewpoint - Roche has received approval from the European Commission for a new room-temperature stable tablet formulation of Evrysdi® (risdiplam) for the treatment of spinal muscular atrophy (SMA), enhancing treatment flexibility and convenience for patients [1][2]. Company Overview - Roche is a leading biotechnology company focused on developing innovative medicines and diagnostics, with a strong emphasis on neuroscience and chronic disease management [10][12]. Product Details - The new 5mg Evrysdi tablet can be taken with or without food, does not require refrigeration, and is suitable for individuals aged two years and older who weigh at least 20kg (44 lbs) [1][4]. - Evrysdi is designed to increase and sustain the production of SMN protein, critical for maintaining healthy motor neurons, thereby improving the course of SMA [2][6]. Clinical Development - The approval of the tablet formulation is based on a bioequivalence study demonstrating that it provides the same efficacy and safety as the original oral solution [3][8]. - Over 18,000 individuals with SMA have been treated with Evrysdi globally, highlighting its established efficacy and safety profile [2][7]. Industry Context - SMA is a severe neuromuscular disease affecting approximately one in 10,000 babies, leading to significant muscle weakness and potential fatality [9]. - Roche's commitment to neuroscience includes investigating multiple treatments for various neurological disorders, including SMA [11].

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety demonstrated in available oral solution Evrysdi is the only non-invasive disease-modifying SMA treatment, with more than 18,000 people with SMA treated globally to date Basel, 04 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for Evrysdi® (risdiplam) to incl ...